Trials / Withdrawn
WithdrawnNCT01317966
Recombinant Human Interleukin-11 Combination Low-dose Rituximab in Immune Thrombocytopenia
A Multicentre Investigation of Recombinant Human Interleukin-11 (rhIL-11) Combination Low-dose Rituximab in Management of Steroid-Resistant/Relapsed Immune Thrombocytopenia (ITP)
- Status
- Withdrawn
- Phase
- —
- Study type
- Observational
- Enrollment
- 0 (actual)
- Sponsor
- Ming Hou · Academic / Other
- Sex
- All
- Age
- 16 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine whether Recombinant Human Interleukin-11 (rhIL-11) Combination Low-dose Rituximab prednisone are effective and safe in the management of Steroid-Resistant/Relapsed Immune Thrombocytopenia (ITP).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | rhIL-11 | Recombinant Human Interleukin-11 (rhIL-11) Combinating Low-dose Rituximab |
Timeline
- Start date
- 2011-03-01
- Primary completion
- 2011-12-01
- Completion
- 2012-03-01
- First posted
- 2011-03-18
- Last updated
- 2016-04-20
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT01317966. Inclusion in this directory is not an endorsement.